Skip to main content

Table 3 Secondary outcomes

From: Arginine supplementation in prevention of necrotizing enterocolitis in the premature infant: an updated systematic review

Name of study Outcome Arginine group Placebo/control RR, 95% CI
Amin et al. [30] RDS 48/75 (64) 51/77 (66) 0.97 (0.77-1.22)
Polycarpou et al. [31] RDS 31/40 (77.5) 35/43 (81.4) 0.95 (0.76-1.19)
Amin et al. [30] IVH grade III and IV 3/75 (4) 3/77 (4) 1.03 (0.21-4.93)
Polycarpou et al. [31] IVH grade III and IV 9/40 (22.5) 12 (27.9) 0.81 (0.38-1.71)
Amin et al. [30] Total PDA 46/75 (61) 45/77 (58) 1.13 (0.59-2.16)
Amin et al. [30] PDA treated with indomethacin 33/75 (44) 38/77 (49) 0.89 (0.63-1.25)
Amin et al. [30] PDA treated surgically 15/75 (20) 13/77 (17) 1.18 (0.61-2.32)
Amin et al. [30] Sepsis 9/75 (12) 11/77 (14) 0.84 (0.37-1.91)
Amin et al. [30] Hypotension after 24 h age 8/75 (11) 8/77 (10) 1.03 (0.37-2.90)
  1. Values are presented as No. (%) unless otherwise indicated.
  2. Abbreviations: IVH Intraventricular hemorrhage, ND No data, PDA Patent ductus arteriosus, RDS Respiratory distress syndrome.